LivaNova Q3 revenue $286M (+13.3% YoY); raises full-year guidance

LivaNova PLC

2023-Q3 EPS reported $0.02 revenue$843,413,000

Revenue $286.1M, up 13.3% reported and 12.1% constant currency vs prior year.
GAAP diluted loss per share $0.14; adjusted diluted EPS $0.73.
Received FDA 510(k) clearance and CE Mark for Essenz In-Line Blood Monitor.
Raised full-year 2023 revenue and adjusted diluted EPS guidance.
Double-digit revenue growth across all regions and three business units.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LivaNova PLC reported the quarter ended September 30, 2023 results: revenue $286.1 million, EPS $0.73. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $286.1 million
EPS: $0.73
Guidance: raised
Result: reported results

Exact text from the filing

Third-quarter revenue of $286.1 million increased 13.3% on a reported basis and increased 12.1% on a constant-currency basis, as compared to the prior-year period

View on SEC.gov

Browse all earnings releases →

LivaNova PLC filing history →

Source: SEC EDGAR

accession 0001639691-23-000108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.